Levodropropizine Capsules

1. This product is a peripheral antitussive drug, which exerts an antitussive effect by selectively inhibiting the peripheral C-fibers of the trachea and bronchus. Its site of action is at sites associated with sensory neuropeptides in the peripheral nodes. It has a strong antitussive effect and lasts for a long time. Since it has no effect on β-adrenergic receptors, M cholinergic receptors and opioid receptors, it has fewer adverse reactions of central inhibition and is an efficient and safe antitussive drug. 2. Subacute and long-term toxicity to rats and dogs 2. The test data showed that the main phenomena during the medication period were salivation, decreased food intake and weight in rats, central sedation, peripheral vasodilation and increased heart rate in dogs; high doses were hepatotoxic to both animals. The test found that the maximum tolerated oral dose of the two animals was 24 mg/kg/d, which is 10 times the clinical dose. Levodropropizine has a slight effect only at 30 times the clinical dose.

The main ingredient of this product is levoproprazine. Chemical name: (-)-3-(4-phenyl-1-piperazinyl)-1,2-propylene glycol Molecular weight: C13H20N2O2

This product is a hard capsule containing white granules.

Dry cough and persistent cough caused by respiratory diseases such as upper respiratory tract infection, pharyngitis, interstitial pneumonia, bronchial asthma and bronchitis.

Oral administration. Adults: 60 mg each time, 3 times a day.

Adverse reactions are rare, mainly manifested as gastrointestinal reactions, nausea, upper abdominal pain, indigestion, vomiting, diarrhea, central nervous system reactions, fatigue, dizziness, drowsiness, headache, palpitations, dry mouth, etc., occasionally visual impairment, rash, dyspnea are rare. Transient elevation of transaminase can be seen at high doses.

1. It is contraindicated for those who are known or may be allergic to this type of drug; 2. It is contraindicated for those with excessive sputum or decreased mucociliary clearance function; 3. It is contraindicated for pregnant women and lactating women.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

1. Pharmacological studies on experimental animals have shown that this product is rapidly absorbed by the nervous system. 2. It also affects the hypoglycemic effect of insulin and digestive system drugs. 3. For particularly sensitive patients, caution should be exercised when taking inhibitory drugs at the same time. 4. Clinical studies have not found any adverse effects on the simultaneous use of other drugs for the treatment of bronchopneumonia.

Keep away from light and store in sealed container.

60mg

12 months

Heilongjiang Wusulijiang Pharmaceutical Co., Ltd. Harbin Branch

• Founded in:

  2001-07-23

• Address:

  No. 39, Bohai Road, Central Area, Haping Road, Harbin Development Zone

• Tax NO.:

  91230199731340543C

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view